Other Events ·
On September 14, 2026, Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 clinical trial for…
CTNMContineum Therapeutics, Inc.
On September 14, 2026, Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 clinical trial for JNJ-5120/PIPE-307 failed to meet its primary efficacy endpoint in treating major depressive disorder. The drug was well-tolerated with no new safety signals, but Johnson & Johnson continues to evaluate prespecified exploratory endpoints to determine next steps. Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for inflammatory and fibrotic diseases.